Stock Movers Blue Owl Drops; Grail Sinks; Opendoor Rises
Feb 20, 2026
A rundown of dramatic stock moves tied to private credit strain and a halted data-center deal. A biotech maker sees its multi-cancer test fail a key trial benchmark and tumbles. A tech-driven real estate marketplace posts a revenue beat that lifts its shares. Brief notes on earnings misses from a longtime internet company round out the market highlights.
AI Snips
Chapters
Transcript
Episode notes
Private Credit Vulnerabilities Exposed
- Blue Owl's troubles highlight fragility in the private credit market beyond a single firm.
- Restricting redemptions and asset sales signal valuation and liquidity stress across alternatives.
Exercise Caution With Private Credit Allocations
- Avoid treating private credit like traditional liquid assets in retail portfolios.
- Be cautious about redemption terms and hidden liquidity risks when allocating to alternatives.
Clinical Setback Crushes Grail Stock
- Grail's multi-cancer blood test failed its primary endpoint, triggering a steep stock decline.
- The trial setback outweighed slightly better-than-lowered earnings and halved the market value in pre-market trading.